ESMO 2025 | Personalized neoantigen vaccines with PD-1 therapy in melanoma
Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, comments on the future of personalized neoantigen cancer vaccines and their possible incorporation with anti-PD-1 based therapy in the near future. Promising data from a randomized trial in stage three melanoma, which demonstrated the efficacy of combining intismeran autogene, a vaccine, with pembrolizumab, highlight the potential of cancer vaccines in this space. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think where we hope to end up with personalized new antigen cancer vaccines is to incorporate them with anti-PD-1 based therapy in the near future. The most compelling data that’s been presented to date is a randomized phase two trial in stage three melanoma with a very similar design to that trial, which was two to one randomization of a vaccine that’s called intismeran (autogene) plus pembrolizumab versus pembrolizumab alone...
I think where we hope to end up with personalized new antigen cancer vaccines is to incorporate them with anti-PD-1 based therapy in the near future. The most compelling data that’s been presented to date is a randomized phase two trial in stage three melanoma with a very similar design to that trial, which was two to one randomization of a vaccine that’s called intismeran (autogene) plus pembrolizumab versus pembrolizumab alone. That data showed an improved relapse-free survival and disease-free survival. There’s a randomized phase three trial that’s completed, and we hope we’ll have data in the coming year or so. And indeed, if we do, and that’s a positive study, then that would be the first chance to actually have an approved agent in that category of therapeutic that would be available to our patients. So I think that’s the very near future, hopefully, of neoantigen vaccines and melanoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
